- Poison control centers across the United States are witnessing a concerning increase in inquiries related to semaglutide, an injectable medication used for diabetes management and weight loss.
- Reports of inadvertent overdoses have led to hospitalizations in some cases, with symptoms including intense nausea, vomiting and abdominal discomfort.
- Data from America’s Poison Centers reveals a startling 15-fold increase in semaglutide-related calls between January and November, primarily attributed to dosage errors, amid concerns over the safety of compounded formulations of the drug.
Semaglutide, a glucagon-like peptide-1 receptor agonist or GLP-1 analog, gained approval from the Food and Drug Administration (FDA) in 2017.
Folllow the link below to Medical News Today to read the full story:
Information source: https://www.medicalnewstoday.com